<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39434043</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database.</ArticleTitle><Pagination><StartPage>2905</StartPage><MedlinePgn>2905</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2905</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-20297-z</ELocationID><Abstract><AbstractText>Continuous surveillance and risk assessment of inactivated Coronavirus Disease 2019 (COVID-19)) vaccines provide an understanding of their safety profiles, guide vaccination strategy and public health policy. This study aims to analyze the characteristics and prevalence of officially reported serious adverse events following immunization (AEFIs) with inactivated COVID-19 vaccines by System Organ Class (SOC), age, and sex.To achieve this aim, a retrospective observational study was conducted between February 14th, 2021, and June 30th, 2022. Reported AEFIs were evaluated for data completeness. Causality assessment adhered to the World Health Organization guidelines.Findings revealed that the AEFIs occurrence did not significantly differ between vaccines used (ChAdOx1 vs. BNT162b2), sex, or SOC. The most prevalent AEFIs were vascular disorders (37%), followed by cardiac (25%) and nervous system disorders (14%). The adverse events were predominantly reported post-vaccination with the BNT162b2 vaccine, mainly after the first dose. The mean age was highest for miscellaneous disorders (70 ± 21.7 years) and the lowest for nervous system (46 ± 22 years) and immune system disorders (45 ± 19 years). Age differences were statistically different for vascular disorders (p = 0.003) and immune system disorders (p = 0.012).In conclusion, ongoing surveillance and risk assessment of the vaccine's safety profile is crucial for detecting potential safety signals. Active surveillance of the reported serious AEFIs is highly needed to support evidence-based vaccination strategies and maintain public confidence in immunization programs.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, Faculty of Science, Section 1, Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality Assurance of Pharmaceutical Products Department, Lebanese Ministry of Public Health, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iskandar</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Lebanese University, P.O. Box 6573/14, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watfa</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Quality Assurance of Pharmaceutical Products Department, Lebanese Ministry of Public Health, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeitoun</LastName><ForeName>Abeer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Quality Assurance of Pharmaceutical Products Department, Lebanese Ministry of Public Health, Beirut, Lebanon. abeer.zeitoun@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>B5S3K2V0G8</RegistryNumber><NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007861" MajorTopicYN="N" Type="Geographic">Lebanon</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events following immunization</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>7</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434043</ArticleId><ArticleId IdType="pmc">PMC11495130</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-20297-z</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-20297-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076774</ArticleId><ArticleId IdType="pubmed">33936564</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations? https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations. Accessed 8 Jul 2022.</Citation></Reference><Reference><Citation>Viveiros-Rosa SG, Mendes CDS, Farfán-Cano GG, El-Shazly M. The race for clinical trials on Omicron-based COVID-19 vaccine candidates: updates from global databases. Narra J. 2022;2(3):e88. 10.52225/narra.v2i3.88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10914133</ArticleId><ArticleId IdType="pubmed">38449904</ArticleId></ArticleIdList></Reference><Reference><Citation>Republic of Lebanon Ministry of Public Health. Lebanon National Deployment and Vaccination Plan for COVID-19 Vaccines. https://www.moph.gov.lb/userfiles/files/Prevention/COVID19%20Vaccine/Lebanon%20NDVP-%20Feb%2016%202021.pdf. Accessed 8 Jul 2022.</Citation></Reference><Reference><Citation>Ministry of Public Health. Pharmacovigilance System in Lebanon. 2021. https://www.moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon. Accessed 8 Jul 2022.</Citation></Reference><Reference><Citation>World Health Organization. Regional Office for the Western Pacific. Immunization safety surveillance: guidelines for immunization program managers on surveillance of adverse events following immunization. 3rd edition. Published online 2016. https://apps.who.int/iris/handle/10665/208262. Accessed 8 Jul 2022.</Citation></Reference><Reference><Citation>World Health Organization (WHO). COVID-19 Vaccines: safety surveillance manual. Published online 2020. https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines_introduction_manual.pdf. Accessed 8 Jul 2022.</Citation></Reference><Reference><Citation>Zeitoun A, Hallit S, Chehade S, Ibrahim A, Helali M, Allam C, Karam R. A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study. J Pharm Policy Pract. 2023;16(1):24. 10.1186/s40545-023-00528-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9942625</ArticleId><ArticleId IdType="pubmed">36810279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F, Chen X, Cheng EW. Contextualized impacts of an infodemic on vaccine hesitancy: the moderating role of socioeconomic and cultural factors. Inf Process Manag. 2022;59(5):103013. 10.1016/j.ipm.2022.103013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286777</ArticleId><ArticleId IdType="pubmed">35874146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Public Health - Quality Assurance of Pharmaceutical Products - Pharmacovigilance Program. Adverse Events Following Immunization for COVID-19 Vaccines in Lebanon: February 14th, 2021 to June 30th, 2022. https://www.moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon. Published online 2022.</Citation></Reference><Reference><Citation>Republic of Lebanon Ministry of Public Health. Ministry of public health: calling 1214 and 1787 became free of charge. http://www.refugees-lebanon.org/uploads/poster/poster_161728344494.pdf.</Citation></Reference><Reference><Citation>IMPACT. https://covax.moph.gov.lb/impactmobile/vaccine. Accessed 5 May 2022.</Citation></Reference><Reference><Citation>Impact Open Data. https://impact.cib.gov.lb/home. Accessed 9 May 2022.</Citation></Reference><Reference><Citation>Aboka D. VigiFlow, introduction and basic features. Uppsala monitoring centre. https://who-umc.org/media/165665/1-introduction-and-basic-features-of-vigiflow.pdf.</Citation></Reference><Reference><Citation>VigiFlow. https://vigiflow.who-umc.org/searchicsrs.</Citation></Reference><Reference><Citation>Ministry of Public Health, Republic of Lebanon. Serious Adverse Events Following Immunization AEFIs - Karar 603/1. https://www.moph.gov.lb/userfiles/files/Laws%26Regulations/Karar%20603-2021.pdf. Published online 2021.</Citation></Reference><Reference><Citation>World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd edition, 2019 update. Geneva: World Health Organization. 2019. https://apps.who.int/iris/handle/10665/340802. Accessed 14 Apr 2022.</Citation></Reference><Reference><Citation>Mishra A, Komut O, Kumar A, Ete T, Megeji RD. Acute myocardial infarction after COVID-19 vaccination: a case report. Cureus. 2022;14(5):e25536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246448</ArticleId><ArticleId IdType="pubmed">35800833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura Y, Yoshimachi F, Nanao T, Kasai S, Ikari Y. A case of ST segment elevation myocardial infarction within 24 h of a third dose of COVID-19 mRNA vaccine. Cardiovasc Revasc Med. 2023;53:S313-16. 10.1016/j.carrev.2022.06.012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197822</ArticleId><ArticleId IdType="pubmed">35718694</ArticleId></ArticleIdList></Reference><Reference><Citation>Maadarani O, Bitar Z, Elzoueiry M, Nader M, Abdelfatah M, Zaalouk T, et al. Myocardial infarction post COVID-19 vaccine–coincidence, Kounis syndrome or other explanation–time will tell. JRSM Open. 2021;12(8):20542704211025260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361528</ArticleId><ArticleId IdType="pubmed">34394944</ArticleId></ArticleIdList></Reference><Reference><Citation>Showkathali R, Yalamanchi R, Narra L, Vinayagamoorthy N, Gunasekaran S, Nayak R, et al. Coronary thrombo-embolic events after covid-19 vaccination-a single centre study. Indian Heart J. 2022;74(2):131–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808476</ArticleId><ArticleId IdType="pubmed">35122777</ArticleId></ArticleIdList></Reference><Reference><Citation>Botros MB, Narvaez-Guerra O, Aurigemma GP, Harrington C. STEMI following MRNA COVID-19 vaccination. J Am Coll Cardiol. 2022;79(9Supplement):2341–234140.</Citation></Reference><Reference><Citation>Gundry SR. Observational findings of PULS cardiac test findings for inflammatory markers in patients receiving mRNA vaccines. Circulation. 2021;144(Suppl1):A10712–1071241.</Citation></Reference><Reference><Citation>Rathore V, Singh N, Mahat RK, Kocak MZ, Fidan K, Ayazoglu TA, et al. Risk factors for acute myocardial infarction: a review. Ejmi. 2018;2(1):1–7.</Citation></Reference><Reference><Citation>Jeet Kaur R, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, et al. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Int J Gen Med. 2021;14:3909–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8326931</ArticleId><ArticleId IdType="pubmed">34349544</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadiq W, Waleed MS, Suen P, Chalhoub MN. Cardiopulmonary arrest after COVID-19 vaccination: a case report. Cureus. 2022;14(1). 10.7759/cureus.21141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8831382</ArticleId><ArticleId IdType="pubmed">35165592</ArticleId></ArticleIdList></Reference><Reference><Citation>Adabag AS, Luepker RV, Roger VL, Gersh BJ. Sudden cardiac death: epidemiology and risk factors. Nat Reviews Cardiol. 2010;7(4):216–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014372</ArticleId><ArticleId IdType="pubmed">20142817</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann V, Jouven X, Narayanan K, Piot O, Chugh SS, Albert CM, Marijon E. Association between atrial fibrillation and sudden cardiac death: pathophysiological and epidemiological insights. Circul Res. 2020;127(2):301–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32833581</ArticleId></ArticleIdList></Reference><Reference><Citation>Baroletti S, Dell’Orfano H. Medication adherence in Cardiovascular Disease. Circulation. 2010;121(12):1455–8. 10.1161/CIRCULATIONAHA.109.904003.</Citation><ArticleIdList><ArticleId IdType="pubmed">20351303</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M, Cheema HA, Khan MHA, Shahid H, Ali MS, Hassan U, et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: a systematic review 2022;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912977</ArticleId><ArticleId IdType="pubmed">35291413</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionne A, Sperotto F, Chamberlain S, Baker AL, Powell AJ, Prakash A, et al. Association of myocarditis with BNT162b2 messenger RNACOVID-19 vaccine in a case series of children. JAMA Cardiol. 2021;6(12):1446–50 w. Annals of medicine and surgery, 76,103486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356143</ArticleId><ArticleId IdType="pubmed">34374740</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymans S, Cooper LT. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Reviews Cardiol. 2022;19(2):75–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656440</ArticleId><ArticleId IdType="pubmed">34887571</ArticleId></ArticleIdList></Reference><Reference><Citation>Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8683843</ArticleId><ArticleId IdType="pubmed">34916207</ArticleId></ArticleIdList></Reference><Reference><Citation>Focus on Myocarditis and Pericarditis after COVID-19 mRNA Vaccines. https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/11/myocarditis-pericarditis-mrna-vaccines.pdf?sc_lang=en%20. Published online 2022. </Citation></Reference><Reference><Citation>Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNAvaccination in the USA: a cohort study in claims databases. Lancet. 2022;399(10342):2191–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9183215</ArticleId><ArticleId IdType="pubmed">35691322</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Kornowski R. Myocarditis after Covid-19 vaccination in a large health care organization. N Eng J Med. 2021;385(23):2132–9. 10.1056/nejmoa2110737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531986</ArticleId><ArticleId IdType="pubmed">34614329</ArticleId></ArticleIdList></Reference><Reference><Citation>Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far? Children. 2021;8(7):607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8305058</ArticleId><ArticleId IdType="pubmed">34356586</ArticleId></ArticleIdList></Reference><Reference><Citation>WebMD. Vascular Disease. WebMD. Published 2021. https://www.webmd.com/heart-disease/vascular-disease. Accessed 7 Aug 2022.</Citation></Reference><Reference><Citation>Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, Dray-Spira R. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. JAMA. 2022;327(1):80–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609457</ArticleId><ArticleId IdType="pubmed">34807248</ArticleId></ArticleIdList></Reference><Reference><Citation>Alammar MA. Ischemic stroke after AstraZeneca (Covid-19) vaccination. Saudi Med J. 2021;42(10):1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129252</ArticleId><ArticleId IdType="pubmed">34611009</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoon KC, Chan DWS. Childhood stroke after influenza vaccination. Proc Singapore Healthc. 2012;21(4):297–300.</Citation></Reference><Reference><Citation>de Mélo Silva Jr ML, Lopes DP. Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report. Acta Neurol Scand. 2021;144(6):717–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444739</ArticleId><ArticleId IdType="pubmed">34273119</ArticleId></ArticleIdList></Reference><Reference><Citation>Assiri SA, Althaqafi RM, Alswat K, Alghamdi AA, Alomairi NE, Nemenqani DM, et al. Post COVID-19 vaccination-associated neurological complications. Neuropsychiatr Dis Treat. 2022;18:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8818972</ArticleId><ArticleId IdType="pubmed">35140464</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines). Published online 2021. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf. Accessed 7 Aug 2022.</Citation></Reference><Reference><Citation>Tobaiqy M, MacLure K, Elkout H, Stewart D. Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database. Vaccines. 2021;9(11):1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624459</ArticleId><ArticleId IdType="pubmed">34835256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheyrandish S, Rastgar A, Arab-Zozani M, Sarab GA. Portal vein thrombosis might develop by COVID-19 infection or vaccination: a systematic review of case-report studies. Front Med. 2021;8:794599. 10.3389/fmed.2021.794599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712467</ArticleId><ArticleId IdType="pubmed">34970570</ArticleId></ArticleIdList></Reference><Reference><Citation>Öcal O, Stecher SS, Wildgruber M. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination. Lancet Gastroenterol Hepatol. 2021;6(8):676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8186953</ArticleId><ArticleId IdType="pubmed">34115963</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao SC, Wang CH, Chang KC, Hung MJ, Chen HY, Liao SC. Guillain-​Barré syndrome associated with COVID-19 vaccination. Emerg Infect Dis. 2021;27(12):3175–8. 10.3201/eid2712.211634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632191</ArticleId><ArticleId IdType="pubmed">34648420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccinationin the vaccine safety datalink. JAMA Netw Open. 2022;5(4):e228879–e228879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044108</ArticleId><ArticleId IdType="pubmed">35471572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouattour N, Hdiji O, Sakka S, Fakhfakh E, Moalla K, Daoud S, Mhiri C. Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases. Neurol Sci. 2022;1-7. 10.1007/s10072-021-05733-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601771</ArticleId><ArticleId IdType="pubmed">34796417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Min YG, Shin JY, Kwon YN, Bae JS, Sung JJ, Hong YH. Guillain-Barré syndrome and variants following COVID-19 vaccination: report of 13 cases. Front Neurol. 2022;12:820723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833101</ArticleId><ArticleId IdType="pubmed">35153993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskr Nor Laegeforen. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33928772</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Korn M. Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages. 2021;2(4):165–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223021</ArticleId><ArticleId IdType="pubmed">34192245</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Lobar bleeding with ventricular rupture shortly after first dosage of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages. 2022;3(1):26–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553377</ArticleId><ArticleId IdType="pubmed">34729467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaratnam SA, Ferdi AC, Leaney J, Lee RLK, Hwang YT, Heard R. Acute disseminated encephalomyelitis with bilateral optic neuritis following ChAdOx1 COVID-19 vaccination. BMC Neurol. 2022;22(1):54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8840677</ArticleId><ArticleId IdType="pubmed">35151258</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Ren L. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurol Belgica. 2022;122(3):793–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7849959</ArticleId><ArticleId IdType="pubmed">33527327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kania K, Ambrosius W, Tokarz Kupczyk E, Kozubski W. Acute disseminated encephalomyelitis in a patient vaccinated against SARS-CoV‐2. Ann Clin Transl Neurol. 2021;8(10):2000–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8528462</ArticleId><ArticleId IdType="pubmed">34480527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi V, Bellucci G, Romano A, Bozzao A, Salvetti M. ADEM after ChAdOx1 nCoV-19 vaccine: a case report. Multiple Scler J. 2022;28(7):1151–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">34590902</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Bedlack R. COVID-19–accelerated disease progression in two patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021;64(3):E13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441768</ArticleId><ArticleId IdType="pubmed">34131925</ArticleId></ArticleIdList></Reference><Reference><Citation>Khayat-Khoei M, Bhattacharyya S, Katz J, Harrison D, Tauhid S, Bruso P, et al. COVID-19 mRNA vaccination leading to CNS inflammation: acase series. J Neurol. 2022;269(3):1093–106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8417681</ArticleId><ArticleId IdType="pubmed">34480607</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu BD, Ugolini C, Jha P, Liu B. Two cases of post-Moderna COVID-19 vaccine encephalopathy associated with nonconvulsive status epilepticus. Cureus. 2021;13(7).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8330960</ArticleId><ArticleId IdType="pubmed">34367780</ArticleId></ArticleIdList></Reference><Reference><Citation>Massoud F, Ahmad SF, Hassan AM, Alexander KJ, Al–Hashel J, Arabi M. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): a cross-sectional study. Seizure. 2021;92:2–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343389</ArticleId><ArticleId IdType="pubmed">34391030</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy M, Chandra A, Roy S, Shrotriya C. Optic neuritis following COVID-19 vaccination: coincidence or side-effect?-A case series. Indian J Ophthalmol. 2022;70(2):679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023989</ArticleId><ArticleId IdType="pubmed">35086265</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Estrada C, Gómez‐Figueroa E, Alban L, Arias‐Cárdenas A. Optic neuritis after COVID‐19 vaccine application. Clin Exp Neuroimmunol. 2022;13(2):72–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653244</ArticleId><ArticleId IdType="pubmed">34900001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffry M, Mandava K, Rosario S, Jedidi K, Souayah N. Association between COVID-19 Vaccination and Optic neuritis in adults: a vaccine adverse event reporting system (VAERS) study (P18-12.004). 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393181</ArticleId><ArticleId IdType="pubmed">36055875</ArticleId></ArticleIdList></Reference><Reference><Citation>Motegi S, Kanda T, Takeuchi M. A case of atypical unilateral optic neuritis following BNT162b2 mRNA COVID-19 vaccination. Vaccines. 2022;10(10):1574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9610132</ArticleId><ArticleId IdType="pubmed">36298437</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobczak M, Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022;20(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762434</ArticleId><ArticleId IdType="pubmed">35039051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890485</ArticleId><ArticleId IdType="pubmed">33576785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Lee YK, Kim TE, Hwang I, Jung YH, Lee HR, et al. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021. Euro Surveill. 2021;26(33):2100694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380974</ArticleId><ArticleId IdType="pubmed">34414880</ArticleId></ArticleIdList></Reference><Reference><Citation>Laisuan W. COVID-19 vaccine anaphylaxis: current evidence and future approaches. Front Allergy. 2021;2:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8974674</ArticleId><ArticleId IdType="pubmed">35387045</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols andpolysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533–1540. 8. 10.1016/j.jaip.2018.12.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706272</ArticleId><ArticleId IdType="pubmed">30557713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanillas B, Akdis C, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol. Allergy. 2021;76(6):1617–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33320974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021;51(6):861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251011</ArticleId><ArticleId IdType="pubmed">33825239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide. Dermatol Clin. 2021;39(4):653–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8165093</ArticleId><ArticleId IdType="pubmed">34556254</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson LB, Fu X, Hashimoto D, Wickner P, Shenoy ES, Landman AB, Blumenthal KG. Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines. JAMA Dermatology. 2021;157(8):1000–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223130</ArticleId><ArticleId IdType="pubmed">34160555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson AR, Freeman EE, Blumenthal KG. Urticaria 12 days after COVID-19 mRNA booster vaccination. JAMA. 2022;327(17):1702–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">35420647</ArticleId></ArticleIdList></Reference><Reference><Citation>Triwatcharikorn J, Puaratana-Arunkon T, Punyaratabandhu P, Mongkolpathumrat P, Palapinyo S, Buranapraditkul S, et al. Acute urticariaalone after CoronaVac COVID-19 vaccination should not be a contraindication forrevaccination. Clin Exp Dermatol. 2022;47(4):735–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652927</ArticleId><ArticleId IdType="pubmed">34609771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounis NG. Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin Chem Lab Med (CCLM). 2016;54(10):1545–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">26966931</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Garcia A. Influenza virus vaccine. Reactions. 2014;1523:118–18.</Citation></Reference><Reference><Citation>Kundi H, Murat GÖK, Kiziltunç E, Çetin M. A rarely seen type-I Kounis syndrome caused by tetanus vaccine. Koşuyolu Heart J. 2018;21(1):82–4.</Citation></Reference><Reference><Citation>Özdemir İH, Özlek B, Özen MB, Gündüz R, &amp; Bayturan Ö. Type 1 Kounis syndrome induced by inactivated SARS-COV-2 vaccine. J Emerg Med. 2021;61(4):e71–6. 10.1016/j.jemermed.2021.04.018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103145</ArticleId><ArticleId IdType="pubmed">34148772</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajstra M, Jaroszewicz J, Gąsior M. Acute coronary tree thrombosis after vaccination for COVID-19. Cardiovasc Interv. 2021;14(9):e103–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092130</ArticleId><ArticleId IdType="pubmed">33958175</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal? Diabetes Metab Syndr. 2021;15(3):1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8045430</ArticleId><ArticleId IdType="pubmed">33888439</ArticleId></ArticleIdList></Reference><Reference><Citation>Şancı E, Örçen C, Çelik OM, Özen MT, Bozyel S. Kounis syndrome associated with BNT162b2 mRNA COVID-19 vaccine presenting as ST-elevation acute myocardial infarction. Anatol J Cardiol. 2022;26(1):72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8878946</ArticleId><ArticleId IdType="pubmed">35191390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current availableCOVID-19 vaccinations: pathophysiology, causality, and therapeuticconsiderations. Vaccines. 2021;9(3):221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999280</ArticleId><ArticleId IdType="pubmed">33807579</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19vaccination. N Engl J Med. 2021;384(23):2202–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrashdy F, Tambuwala MM, Hassan SS, Adadi P, Seyran M, Abd El-Aziz TM, et al. Autoimmunity roots of the thrombotic events afterCOVID-19 vaccination. Autoimmun Rev. 2021;20(11):102941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426137</ArticleId><ArticleId IdType="pubmed">34508917</ArticleId></ArticleIdList></Reference><Reference><Citation>See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087975</ArticleId><ArticleId IdType="pubmed">33929487</ArticleId></ArticleIdList></Reference><Reference><Citation>Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood J Am Soc Hematol. 2021;138(4):293–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172307</ArticleId><ArticleId IdType="pubmed">34323940</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleem A, Nadeem AJ. Coronavirus (COVID-19) vaccine-induced immune thrombotic thrombocytopenia (VITT). 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34033367</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara LJ, Vera-Lastra O, Mahroum N, Pineda C, Shoenfeld Y. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin Rheumatol. 2022;41(5):1603–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8979721</ArticleId><ArticleId IdType="pubmed">35378658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020;19(6):102538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131471</ArticleId><ArticleId IdType="pubmed">32268212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mincer DL, Jialal I. Hashimoto Thyroiditis. In: StatPearls. StatPearls Publishing; 2022. http://www.ncbi.nlm.nih.gov/books/NBK4592. Accessed 12 Aug 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">29083758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima Z, Reece BR, Moore JS, Means RT Jr. Autoimmune hemolytic anemia after mRNA COVID vaccine. J Investig Med High Impact Case Rep. 2022;10:23247096211073256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8777324</ArticleId><ArticleId IdType="pubmed">35045762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaignard ME, Lieberherr S, Schoenenberger A, Benz R. Autoimmune hematologic disorders in two patients after mRNA COVID-19 vaccine. Hemasphere. 2021;5(8):e618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8274740</ArticleId><ArticleId IdType="pubmed">34263143</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bruyne S, Van Landeghem S, Schauwvlieghe A, Noens L. Life-threatening autoimmune hemolytic anemia following mRNA COVID-19 vaccination: don’t be too prudent with the red gold. Clin Chem Lab Med (CCLM). 2022;60(6):e125–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35278047</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito S, Ferreira N, Mateus S, Bernardo M, Pinto B, Lourenço A, Grenho F. A case of autoimmune hemolytic anemia following COVID-19 messenger ribonucleic acid vaccination. Cureus. 2021;13(5):e15035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200779</ArticleId><ArticleId IdType="pubmed">34150386</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Aoun S, Motabi I. Cold agglutinin disease after COVID-19 vaccine. Br J Haematol. 2021;195(5):650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444673</ArticleId><ArticleId IdType="pubmed">34176130</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdych TM. A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS-CoV-2 vaccine. Int J Lab Hematol. 2022;44(1):e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444646</ArticleId><ArticleId IdType="pubmed">34258873</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed large local reactions to mRNA-1273 vaccine againstSARS-CoV-2. N Engl J Med. 2021;384(13):1273–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944952</ArticleId><ArticleId IdType="pubmed">33657292</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesqué D, Lopez-Trujillo E, Marcantonio O, Giménez‐Arnau AM, Pujol RM. New‐onset and exacerbations of psoriasis after mRNA COVID‐19 vaccines: two sides of the same coin? J Eur Acad Dermatol Venereol. 2022;36(2):e80–1.</Citation><ArticleIdList><ArticleId IdType="pubmed">34547146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D, Vakirlis E. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021;35(12):e857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447325</ArticleId><ArticleId IdType="pubmed">34363647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa T, Tomomatsu K, Okazaki E, Takeuchi T, Horio Y, Kondo Y, et al. COVID-19 vaccine-associated organizing pneumonia. Respirol Case Rep. 2022;10(5):e0944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8965045</ArticleId><ArticleId IdType="pubmed">35386579</ArticleId></ArticleIdList></Reference><Reference><Citation>May J, Draper A, Aul R. Eosinophilic pneumonia and COVID-19 vaccination. QJM: Int J Med. 2022;115(4):251–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383422</ArticleId><ArticleId IdType="pubmed">35166852</ArticleId></ArticleIdList></Reference><Reference><Citation>Golbets E, Kaplan A, Shafat T, Yagel Y, Jotkowitz A, Awesat J, Barski L. Secondary organizing pneumonia after recovery of mild COVID-19 infection. J Med Virol. 2022;94(1):417–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661567</ArticleId><ArticleId IdType="pubmed">34581458</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post–COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5):799–806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Kim JH, Lee IJ, Kim HI, Park S, Hwang YI, et al. COVID-19 vaccine-related interstitial lung disease: a case study. Thorax. 2022;77(1):102–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">34362838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kewan T, Flores M, Mushtaq K, Alwakeel M, Burton R, Campbell J, et al. Characteristics and outcomes of adverse events after COVID‐19 vaccination. J Am Coll Emerg Physicians Open. 2021;2(5):e12565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8514147</ArticleId><ArticleId IdType="pubmed">34693399</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr A, Hitzenbichler F, Pfeifer M, Hinterberger T, Loew TH, Leinberger B. Saturation rate after vaccination against covid-19. Archives Clin Biomedical Res. 2022;6(2):402–7.</Citation></Reference><Reference><Citation>Tutak AS, Söylemez F, Konuk HB, Cakmak E, Karakaya B, Doğan A, et al. A patient presenting with ARDS after COVID-19 vaccination: aCOVID-19 case report. J Infect Public Health. 2021;14(10):1395–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8170910</ArticleId><ArticleId IdType="pubmed">34175235</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb A, Abdelmalek J, Iwuji K, Nugent K. Acute myocardial injury following COVID-19 vaccination: a case report and review of current evidence from vaccine adverse events reporting system database. J Prim Care Commun Health. 2021;12:21501327211029230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8255555</ArticleId><ArticleId IdType="pubmed">34219532</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JH, Duncan J, Addo A, Smith S, Kovoor J, Tivey D. Influence of COVID-19 vaccines on surgical practice - A rapid review commissioned by RACS. https://www.surgeons.org/-/media/Project/RACS/surgeons-org/files/RACS-FINAL-COVID-19-vaccine-andsurgery.pdf?. Published online 2021. </Citation></Reference><Reference><Citation>Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, et al. Neutropenia as an adverse event following vaccination:results from randomized clinical trials in healthy adults and systematicreview. PLoS One. 2016;11(8):e0157385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974007</ArticleId><ArticleId IdType="pubmed">27490698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>